Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, the trial has also come ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback